In The Know-February 2023

February 2023

Pdf Summary

The February 2023 edition of Ed's List: In The Know highlights several significant studies in the field of gynecologic oncology.<br /><br />One study published in the Journal for ImmunoTherapy of Cancer found that tuning the activation of MSLN-CAR T cells could improve antitumor responses in ovarian cancer models. The study demonstrated that M1xx CAR T cells showed superior antitumor potency and persistence compared to conventional M28z and MBBz CAR T cells. This study suggests that MSLN-CAR T cells expressing a mutated CD3ζ chain could enhance the therapeutic potential for treating ovarian cancer.<br /><br />Another study in the Journal of Clinical Oncology evaluated the maintenance treatment of ovarian cancer with taxanes versus surveillance. The results showed no significant difference in progression-free survival between the two treatment approaches. This study provides insights into the optimal treatment duration for ovarian cancer patients.<br /><br />A study in JAMA Network Open examined the association between frequent aspirin use and ovarian cancer risk in individuals with genetic susceptibility to ovarian cancer. The findings suggest that frequent aspirin use may lower the risk of ovarian cancer regardless of an individual's genetic susceptibility.<br /><br />The American Journal of Obstetrics and Gynecology published a study on the supply of obstetrician-gynecologists and gynecologic oncologists to the US Medicare population. The study found wide geographic variation in the supply and growth rate of these providers, highlighting areas where the supply may not meet current and future demand.<br /><br />These and other studies featured in Ed's List provide valuable insights and advancements in the field of gynecologic oncology.

Keywords

gynecologic oncology

MSLN-CAR T cells

ovarian cancer

antitumor responses

maintenance treatment

taxanes

progression-free survival

frequent aspirin use

genetic susceptibility

obstetrician-gynecologists